Oral therapy for chronic immune thrombocytopenic purpura

Revolade (eltrombopag) is the first oral treatment option for chronic immune thrombocytopenic purpura to be launched in the UK.

Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes.

The dosing schedule is dependent on the individual patient's platelet counts but consists of a once daily oral dose.

The objective of treatment with eltrombopag is to maintain platelet counts above the level for haemorrhagic risk (50000/microlitre).

In most patients, measurable elevations in platelet counts take 1-2 weeks.

View Revolade drug record

Further information: GSK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases